O’Melveny Worldwide

Get to Know Steve

Get to Know Steve

  • In a seven-week televised trial garnering national media attention, defended against the State of Oklahoma's claims in the first case to go to trial against an opioid manufacturer, limiting the State to a trial level judgment of just US$465 million of the US$17.5 billion it sought and then obtaining a reversal and full defense judgment on appeal
  • Obtained appellate reversal and dismissal of US$1.2 billion Medicaid fraud judgment against pharmaceutical manufacturer in action brought by the Arkansas Attorney General
  • Prevailed on appeal from US$330 million judgment in Medicaid fraud action by the Louisiana Attorney General, winning reversal and entry of judgment in favor of pharmaceutical manufacturer
  • Defended a US$74 million constructive fraudulent conveyance action for a hospital and health systems operator in the US Bankruptcy Court for the District of Columbia in a seven-week bench trial, securing a full defense judgment on all claims that was upheld on appeal to the district court
  • Obtained reversal of US$4.5 million consumer fraud judgment against a pharmaceutical manufacturer in a state court action brought by the West Virginia Attorney General
  • Represented major pharmaceutical manufacturers against Medicaid reimbursement, fraud and unfair trade practices claims brought by numerous State Attorneys General
  • Coordinated a multi-firm defense effort for a major pharmaceutical manufacturer against claims for reimbursement of prescription drug payments brought by almost 200 third-party payers in state and federal court
  • Represented medical device manufacturers in multi-state Attorney General investigations
  • Obtained dismissal of nationwide Average Wholesale Price class action against pharmaceutical manufacturer
  • Won reversal of a federal district court remand order on behalf of an over-the-counter manufacturer in an important decision from the 8th Circuit on the scope of CAFA jurisdiction
  • Obtained order striking class claims before any discovery in case alleging violations of Missouri Merchandising Practices Act by over-the-counter manufacturer
  • Secured dismissal of class actions against retirement services providers in ERISA fiduciary litigation challenging the reasonableness of 401(k) plan fee structures
  • Defeated certification of a purported nationwide class action brought by provider alleging illegitimate appropriation of discounted reimbursement by a major health insurance carrier through preferred provider network
  • Obtained dismissal of nationwide class action against a large Medicare Advantage contractor over alleged misclassification of Medicare Part B and Part D drugs
  • Secured dismissal of class action against governing body for college athletics alleging failure to secure integrity of academic instruction offered to intercollegiate athletes
  • Obtained an order setting aside a death sentence in favor of life in prison based on findings of Brady violations by prosecutors after a two-day evidentiary hearing in pro bono representation of capital defendant
  • Following a nine-day bench trial, secured judgment invalidating State of Alabama absentee ballot voting requirements as discriminatory against persons with disabilities during COVID-19 pandemic

Admissions

Bar Admissions

  • District of Columbia
  • Virginia

Court Admissions

  • US District Court for District of Columbia
  • US Court of Appeals, District of Columbia, Fourth, Sixth, Seventh, Eighth, Ninth, and Tenth Circuits
  • US Supreme Court

Education

  • Washington & Lee University, J.D., 1994
  • Williams College, B.A., Political Economy, 1990

Honors & Awards

  • Named a “Litigation Star” (2018, 2024-2026), “National Practice Area Star” (2019-2026), and “Local Litigation Star” (2018-2023) for Product Liability and Recall by Benchmark Litigation
  • Recognized by Chambers USA for Product Liability & Mass Torts (2021-2026)
  • Recommended by Who’s Who Legal (WWL) for Product Liability Defence (2023)
  • Recognized in Washington, DC Super Lawyers for Civil Litigation Defense (2013) and Class Actions and Mass Torts (2014-present)
  • “Life Sciences Star” for Products Liability Litigation and White-Collar/Government Investigations by LMG Life Sciences (2012-present)
  • Ranked by The Legal 500 US as a “Leading Partner” for State Attorneys General (2023-2026) and Product Liability, Mass Tort and Class Action - Defense: Pharmaceuticals and Medical Devices (2024-2026)
  • Recommended by The Legal 500 US for Healthcare: Life Sciences (2022-2025); Product Liability, Mass Tort and Class Action - Defense: Automative/Transport (2023-2026); Product Liability, Mass Tort and Class Action - Defense: Consumer Products (Including Tobacco) (2023-2024, 2026); Product Liability, Mass Tort and Class Action - Defense: Pharmaceuticals and Medical Devices (2023); Product Liability, Mass Tort and Class Action - Defense: Toxic Tort (2023-2024)
  • LMG Life Sciences Product Liability Lawyer of the Year (2021)
  • Law360 Product Liability MVP (2021)
  • Recommended by The Legal 500 US for Dispute Resolution - Product Liability, Mass Tort and Class Action (2016-present) and General Commercial Disputes (2020-2021)
  • Named a Life Sciences “Trailblazer” by The National Law Journal (2020)

Professional Activities

Selected Speaking Engagements

  • Moderator, “Mass Torts Made Imperfect: Is the Tort System Broken?,” Government Investigations & Civil Litigation Institute Annual Meeting (November 19-21, 2024)
  • Panelist, “Lessons from the January 6 Committee: Navigating Parallel Investigations by Congress and Enforcement Agencies,” Government Investigations & Civil Litigation Institute Annual Meeting (November 15-17, 2023)
  • Moderator, “Lessons Learned From the Opioid Litigation,” Government Investigations & Civil Litigation Institute Annual Meeting (November 7-9, 2022)
  • Panelist, “Opioids, Public Nuisance, and the Evolution of Mass Torts,” New York City Bar Association (May 10, 2022)
  • Moderator, “Attorney General Enforcement Trends,” Government Investigations & Civil Litigation Institute Annual Meeting (October 9-11, 2017)
  • International Association of Defense Counsel Mid-Year Meeting (2015)
  • ABA Environmental, Mass Torts & Products Liability Litigation Committees’ Joint CLE Seminar (2015)
  • ACI Drug and Medical Device Conference (2014)
  • HarrisMartin’s Mass Tort Litigation Conference with Judge Marina Corodemus (Ret.) (2013, 2014)
  • PhRMA Law Section Annual Meeting (2013)
  • ACI 8th Advanced Summit on Off-Label Communications (2012)
  • ACI Expert Guide to Advertising, eMarketing & Promotions for the Pharmaceutical Industry (2011)
  • ACI 7th National Forum on Off-Label Communications (2010)
  • “Defense Perspectives on Attorney General Pharmaceutical Claims,” LexisNexis/HB Litigation Conferences (2008, 2009)
  • “Ethics & Discovery,” Practising Law Institute (2007, 2009-2015 (Chair))